Last reviewed · How we verify
Bupivacaine HCl collagen-matrix implant
Bupivacaine HCl collagen-matrix implant is a Local anesthetic Small molecule drug developed by Innocoll. It is currently in Phase 3 development for Postoperative pain management following surgical procedures. Also known as: Xaracoll.
Bupivacaine HCl is released from a collagen matrix implant to provide local anesthesia at the surgical site.
Bupivacaine HCl is released from a collagen matrix implant to provide local anesthesia at the surgical site. Used for Postoperative pain management following surgical procedures.
At a glance
| Generic name | Bupivacaine HCl collagen-matrix implant |
|---|---|
| Also known as | Xaracoll |
| Sponsor | Innocoll |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Surgery |
| Phase | Phase 3 |
Mechanism of action
The drug combines bupivacaine, a long-acting local anesthetic, with a biodegradable collagen matrix that serves as a depot delivery system. The collagen matrix gradually releases bupivacaine over time, providing prolonged local anesthetic effect at the implantation site to reduce postoperative pain. This approach aims to minimize systemic exposure while maintaining localized anesthetic coverage during the critical postoperative period.
Approved indications
- Postoperative pain management following surgical procedures
Common side effects
- Local site reactions
- Infection at implant site
- Delayed wound healing
- Systemic bupivacaine toxicity
Key clinical trials
- Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty (PHASE3)
- Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair (PHASE3)
- Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty (PHASE1)
- Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy (PHASE2)
- Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine HCl collagen-matrix implant CI brief — competitive landscape report
- Bupivacaine HCl collagen-matrix implant updates RSS · CI watch RSS
- Innocoll portfolio CI
Frequently asked questions about Bupivacaine HCl collagen-matrix implant
What is Bupivacaine HCl collagen-matrix implant?
How does Bupivacaine HCl collagen-matrix implant work?
What is Bupivacaine HCl collagen-matrix implant used for?
Who makes Bupivacaine HCl collagen-matrix implant?
Is Bupivacaine HCl collagen-matrix implant also known as anything else?
What drug class is Bupivacaine HCl collagen-matrix implant in?
What development phase is Bupivacaine HCl collagen-matrix implant in?
What are the side effects of Bupivacaine HCl collagen-matrix implant?
What does Bupivacaine HCl collagen-matrix implant target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Innocoll — full pipeline
- Therapeutic area: All drugs in Pain management / Surgery
- Indication: Drugs for Postoperative pain management following surgical procedures
- Also known as: Xaracoll
- Compare: Bupivacaine HCl collagen-matrix implant vs similar drugs
- Pricing: Bupivacaine HCl collagen-matrix implant cost, discount & access